In this podcast episode, listen to Karim Fizazi, MD, PhD, and Alicia K. Morgans, MD, MPH, as they discuss clinical implications of the latest data from ASCO 2021 on using androgen receptor–directed therapy for the treatment and management of patients with nonmetastatic castration-resistant prostate cancer.
In this episode, Karim Fizazi, MD, PhD, and Alicia K. Morgans, MD, MPH, discuss the clinical implications of the latest data on androgen receptor–targeting agents in the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). Topics include:
Presenters:
Karim Fizazi, MD, PhD
Full Professor
Cancer Medicine
Gustave Roussy
Villejuif, France
Alicia K. Morgans, MD, MPH
Associate Professor
Division of Oncology
Department of Medicine
Northwestern University
Chicago, Illinois
Link to full program, including downloadable slides:
https://bit.ly/36IEnNE